Abstract:Researchers have adopted model-centric artificial intelligence (AI) approaches in cheminformatics by using newer, more sophisticated AI methods to take advantage of growing chemical libraries. It has been shown that complex deep learning methods outperform conventional machine learning (ML) methods in QSAR and ligand-based virtual screening but such approaches generally lack explanability. Hence, instead of developing more sophisticated AI methods (i.e., pursuing a model-centric approach), we wanted to explore the potential of a data-centric AI paradigm for virtual screening. A data-centric AI is an intelligent system that would automatically identify the right type of data to collect, clean and curate for later use by a predictive AI and this is required given the large volumes of chemical data that exist in chemical databases – PubChem alone has over 100 million unique compounds. However, a systematic assessment of the attributes and properties of suitable data is needed. We show here that it is not the result of deficiencies in current AI algorithms but rather, poor understanding and erroneous use of chemical data that ultimately leads to poor predictive performance. Using a new benchmark dataset of BRAF ligands that we developed, we show that our best performing predictive model can achieve an unprecedented accuracy of 99% with a conventional ML algorithm (SVM) using a merged molecular representation (Extended + ECFP6 fingerprints), far surpassing past performances of virtual screening platforms using sophisticated deep learning methods. Thus, we demonstrate that it is not necessary to resort to the use of sophisticated deep learning algorithms for virtual screening because conventional ML can perform exceptionally well if given the right data and representation. We also show that the common use of decoys for training leads to high false positive rates and its use for testing will result in an over-optimistic estimation of a model’s predictive performance. Another common practice in virtual screening is defining compounds that are above a certain pharmacological threshold as inactives. Here, we show that the use of these so-called inactive compounds lowers a model’s sensitivity/recall. Considering that some target proteins have a limited number of known ligands, we wanted to also observe how the size and composition of the training data impact predictive performance. We found that an imbalance training dataset where inactives outnumber actives led to a decrease in recall but an increase in precision, regardless of the model or molecular representation used; and overall, we observed a decrease in the model’s accuracy. We highlight in this study some of the considerations that one needs to take into account in future development of data-centric AI for CADD.

SAE-SV: A Stacked-AutoEncoder and Soft Voting Joint Approach Based on Small Dataset with High Dimensions for Inhibitory Potency Prediction

Transfer inhibitory potency prediction to binary classification: A model only needs a small training set

Co-VAE: Drug-Target Binding Affinity Prediction by Co-Regularized Variational Autoencoders.

Small dataset solves big problem: An outlier-insensitive binary classifier for inhibitory potency prediction

IVS2vec: A tool of Inverse Virtual Screening based on word2vec and deep learning techniques

Optimization of a Multi-Feature AI Ensemble and Voting System for MAPKAPK2 Inhibitor Discovery

Addressing data imbalance problems in ligand-binding site prediction using a variational autoencoder and a convolutional neural network

PED: a novel predictor-encoder-decoder model for Alzheimer drug molecular generation

A novel microbe-drug association prediction model based on stacked autoencoder with multi-head attention mechanism

Exploration and Augmentation of Pharmacological Space Via Adversarial Auto-Encoder Model for Facilitating Kinase-Centric Drug Development

ADMET Evaluation in Drug Discovery. 19. Reliable Prediction of Human Cytochrome P450 Inhibition Using Artificial Intelligence Approaches

MSDSE: Predicting drug-side effects based on multi-scale features and deep multi-structure neural network

Ligand Classifier of Adaptively Boosting Ensemble Decision Stumps (LiCABEDS) and its application on modeling ligand functionality for 5HT-subtype GPCR families

Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening

Accelerating Molecular Docking using Machine Learning Methods

SAEROF: an ensemble approach for large-scale drug-disease association prediction by incorporating rotation forest and sparse autoencoder deep neural network

TransVAE-DTA: Transformer and variational autoencoder network for drug-target binding affinity prediction

Prediction of Drug-Likeness Using Deep Autoencoder Neural Networks.

Synergizing Chemical Structures and Bioassay Descriptions for Enhanced Molecular Property Prediction in Drug Discovery

Redefining the Game: MVAE-DFDPnet’s Low-Dimensional Embeddings for Superior Drug-Protein Interaction Predictions

Establishing the foundations for a data-centric AI approach for virtual drug screening through a systematic assessment of the properties of chemical data